AN2 Therapeutics ANTX 深 沪
等待开盘 08-27 09:30:00 美东时间
1.15
+0.025
+2.22%
华盛通- 最 高1.16
- 今 开1.16
- 成交量 3.10万股
- 最 低 1.12
- 昨 收 1.125
- 总市值 3470.21万
- 52周最高 1.675
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.975
- 委 比 53.48%
- 总股本 3017.57万
- 历史最高 23.58
- 量 比 0.37
- 振 幅 3.56%
- 历史最低 0.87
- 每 手 1
- 风险率 0.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AN2 Therapeutics Q2 EPS $(0.21) Beats $(0.30) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.30) by 30.69 percent. This is a 56.25 percent increase over losses of $(0.48) per share from
08-13 04:20
Anterix Sets First Quarter Fiscal 2026 Earnings Conference Call for Wednesday, August 13, at 9:00 a.m. ET
<p>Anterix (NASDAQ: ATEX) announced it will host a conference call on August 13, 2025, at 9:00 a.m. ET to discuss its first quarter fiscal 2026 results. A press release will be issued on August 12, 2025. Interested participants must pre-register to join the live Q&A session. The call will be webcast live and available on Anterix’s Investor Relations website. A replay will be posted afterward. Anterix specializes in 900 MHz broadband solutions for...
07-22 15:30
AN2 Therapeutics Completed Its 200-patient Observational Study In Acute Melioidosis. The Study Evaluated Patients Receiving The Current Standard Of Care: IV Meropenem Or Ceftazidime
Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraboroleObservational Study funded by the National Institutes of Health
06-30 19:11
AN2 Therapeutics Unveils Updated Investor Presentation
AN2 Therapeutics, Inc. ( ($ANTX) ) just unveiled an announcement. On June 11, 2...
06-11 19:59
AN2 Therapeutics Elects New Directors at Annual Meeting
AN2 Therapeutics, Inc. ( ($ANTX) ) has shared an announcement. On May 22, 2025,...
05-28 05:09
AN2 Therapeutics Q1 GAAP EPS $(0.35) Misses $(0.26) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.26) by 34.62 percent. This is a 37.5 percent increase over losses of $(0.56) per share from
05-14 06:01
快讯 | AN2 Therapeutics Inc：预计现金流将资助运营至2028年
AN2 Therapeutics Inc: Cash Runway Anticipated to Fund Operations Into 2028
05-14 04:02
快讯 | AN2 Therapeutics报告2025财年第一季度财务业绩以及近期的业务和科学亮点
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Busine...
05-14 04:01
AN2 Therapeutics Faces Setback in Phase 3 Study
AN2 Therapeutics, Inc. ( ($ANTX) ) has issued an update. AN2 Therapeutics annou...
05-02 04:48
AN2 Therapeutics Reports 2024 Financials and Pipeline Progress
AN2 Therapeutics, Inc. ( ($ANTX) ) has released its Q4 earnings. Here is a brea...
04-04 11:53
